Four leading hemophilia organizations say hemophilia patients can receive the COVID-19 vaccine and note that those who have moderate to severe disease should pre-medicate with clotting factor.
“For patients with severe/moderate hemophilia, the injection should be given after a factor VIII (FVIII) or factor IX (FIX) injection,” according to guidance from the World Federation of Hemophilia, the European Association for Haemophilia and Allied Disorders (EAHAD), the European Haemophilia Consortium (EHC) and the U.S. National Hemophilia Foundation.
The groups also advise requesting the thinnest needle possible and applying pressure after the injection, the guidance says. Hemophilia patients are not more at risk because of their bleeding disorder and should talk with their doctors about COVID-19 vaccination, according to the statement.
The advisory also made recommendations for those who have von Willebrand Disease and for those who have rare bleeding disorders.
See the joint statement with patient guidance.
See additional FAQs about COVID-19 vaccines on the NHF website.
